Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

epartments of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd., CVN-6, La Jolla, CA 92037, USA.
Journal of Virology (Impact Factor: 4.65). 02/2006; 80(4):1680-7. DOI: 10.1128/JVI.80.4.1680-1687.2006
Source: PubMed

ABSTRACT The human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 4E10 binds to a linear, highly conserved epitope within the membrane-proximal external region of the HIV-1 envelope glycoprotein gp41. We have delineated the peptide epitope of the broadly neutralizing 4E10 antibody to gp41 residues 671 to 683, using peptides with different lengths encompassing the previously suggested core epitope (NWFDIT). Peptide binding to the 4E10 antibody was assessed by competition enzyme-linked immunosorbent assay, and the K(d) values of selected peptides were determined using surface plasmon resonance. An Ala scan of the epitope indicated that several residues, W672, F673, and T676, are essential (>1,000-fold decrease in binding upon replacement with alanine) for 4E10 recognition. In addition, five other residues, N671, D674, I675, W680, and L679, make significant contributions to 4E10 binding. In general, the Ala scan results agree well with the recently reported crystal structure of 4E10 in complex with a 13-mer peptide and with our circular dichroism analyses. Neutralization competition assays confirmed that the peptide NWFDITNWLWYIKKKK-NH(2) could effectively inhibit 4E10 neutralization. Finally, to limit the conformational flexibility of the peptides, helix-promoting 2-aminoisobutyric acid residues and helix-inducing tethers were incorporated. Several peptides have significantly improved affinity (>1,000-fold) over the starting peptide and, when used as immunogens, may be more likely to elicit 4E10-like neutralizing antibodies. Hence, this study represents the first stage toward iterative development of a vaccine based on the 4E10 epitope.


Available from: Dennis R Burton, May 27, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most attempts to develop synthetic peptide vaccines assume that it is possible to obtain effective vaccine immunogens by making short linear peptides adopt the structures observed when epitopes of pathogens are bound to neutralizing antibodies. Although more than a thousand synthetic peptides have been examined as potential prophylactic vaccines, only 125 peptides have progressed to phase I clinical trials, 30 have made it to phase II trials but not a single one has passed phase III trials and is currently marketed for human use. Reasons for this lack of success include 1) an excessive reliance on continuous epitopes as vaccine candidates, 2) an exaggerated confidence in the specificity of antibodies, 3) the failure to recognize that an operational bias is introduced when monoclonal antibodies are used to characterize epitopes and, 4) a tendency to underestimate the difference between antigenicity and immunogenicity. There clearly is a need to overcome these misconceptions if synthetic peptide vaccines are ever to become a reality.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hydrocarbon stapling can restore bioactive α-helical structure to natural peptides, yielding research tools and prototype therapeutics to dissect and target protein interactions. Here we explore the capacity of peptide stapling to generate high-fidelity, protease-resistant mimics of antigenic structures for vaccine development. HIV-1 has been refractory to vaccine technologies thus far, although select human antibodies can broadly neutralize HIV-1 by targeting sequences of the gp41 juxtamembrane fusion apparatus. To develop candidate HIV-1 immunogens, we generated and characterized stabilized α-helices of the membrane-proximal external region (SAH-MPER) of gp41. SAH-MPER peptides were remarkably protease resistant and bound to the broadly neutralizing 4E10 and 10E8 antibodies with high affinity, recapitulating the structure of the MPER epitope when differentially engaged by the two anti-HIV Fabs. Thus, stapled peptides may provide a new opportunity to develop chemically stabilized antigens for vaccination.
    Nature Structural & Molecular Biology 11/2014; 21(12). DOI:10.1038/nsmb.2922 · 11.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fusion of host and viral membranes is a critical step during infection by membrane-bound viruses. The HIV-1 glycoproteins gp120 (surface subunit) and gp41 (fusion subunit) represent the prototypic system for studying this process; in the prevailing model, the gp41 ectodomain forms a trimeric six-helix bundle that constitutes a critical intermediate and provides the energetic driving for overcoming barriers associated with membrane fusion. However, most structural studies of gp41 variants have been performed either on ectodomain constructs lacking one or more of membrane-associated segments (the fusion peptide, FP, the membrane-proximal external region, MPER, and transmembrane domain, TM), or on variants consisting of these isolated segments alone without the ectodomain. Several recent reports have suggested that the HIV-1 ectodomain, as well as larger construct containing the membrane-bound segments, dissociate from a trimer to a monomer in detergent micelles. Here we compare the properties of a series of gp41 variants to delineate the roles of the ectodomain, FP, and MPER and TM, all in membrane-mimicking environments. We find that these proteins are prone to formation of a monomer in detergent micelles. In one case, we observed exclusive monomer formation at pH 4 but conditional trimerization at pH 7 even at low micromolar (~5 μM) protein concentrations. Liposome release assays demonstrate that these gp41-related proteins have the capacity to induce content leakage, but that this activity is also strongly modulated by pH with much higher activity at pH 4. Circular dichroism, NMR, and binding assays with antibodies specific to the MPER provide insight into the structural and functional roles of the FP, MPER, and TM and their effect on structure within the larger context of the fusion subunit.
    Biochemistry 02/2015; DOI:10.1021/bi501376f · 3.19 Impact Factor